Osteoporosis caused by Glucocorticoid Treatment (DBCOND0129307)

Identifiers

Synonyms

Glucocorticoid Induced Osteoporosis / Steroid-induced osteoporosis / Osteoporosis, Steroid Induced / Osteoporosis caused by glucocorticoid / Osteoporosis caused by corticosteroid / Osteoporosis steroid-induced / Glucocorticoid-induced Osteoporosis / Osteoporosis caused by corticosteroid (disorder) / Osteoporosis due to corticosteroids (disorder) / Osteoporosis / Osteoporosis (disorder) / Osteoporosis NOS (disorder) / Involutional osteoporosis without current pathological fracture / Osteoporosis, unspecified / Osteoporosis NOS / Osteoporosis, unspecified (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Alendronic acid	A bisphosphonate drug that prevents osteoclastic bone resorption which is used for the prevention and treatment of osteoporosis.	Farnesyl pyrophosphate synthasetarget Tyrosine-protein phosphatase non-receptor type 4target Receptor-type tyrosine-protein phosphatase Starget Receptor-type tyrosine-protein phosphatase epsilontarget V-type proton ATPase catalytic subunit Atarget Hydroxylapatitetarget
Denosumab	A RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.	Tumor necrosis factor ligand superfamily member 11target
Nandrolone	An anabolic steroid indicated to increase bone density and muscle mass in patients with osteoporosis.	Androgen receptortarget
Raloxifene	A selective estrogen receptor modulator that is used to prevent and treat osteoporosis and reduce the risk of invasive breast cancer in high-risk postmenopausal women.	Estrogen receptortarget Estrogen receptor betatarget Aldehyde oxidaseenzyme Cytochrome P450 2C8enzyme Cytochrome P450 2B6enzyme Aromataseenzyme Cytochrome P450 3A4enzyme Serpin B9target Trefoil factor 1target UDP-glucuronosyltransferase 1A1enzyme Albumincarrier Alpha-1-acid glycoprotein 1carrier Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 2transporter ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 4transporter UDP-glucuronosyltransferase 1A10enzyme UDP-glucuronosyltransferase 1A8enzyme
Teriparatide	A recombinant parathyroid hormone used for the treatment of osteoporosis.	Parathyroid hormone/parathyroid hormone-related peptide receptortarget Parathyroid hormonetarget
Zoledronic acid	A bisphosphonate used to treat malignancy associated hypercalcemia, multiple myeloma, and bone metastasis from solid tumors.	Farnesyl pyrophosphate synthasetarget Geranylgeranyl pyrophosphate synthasetarget Hydroxylapatitetarget Multidrug resistance-associated protein 1transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05397938	Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis	Alendronic acid Narlumosbart	treatment	2	unknown_status
NCT02472782	Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication	Teriparatide	Not Available	Not Available	completed
NCT03040531	Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis	Alendronic acid	prevention	2 / 3	unknown_status
NCT06395883	Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT06588153	A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China	Denosumab	treatment	4	not_yet_recruiting
NCT04091243	Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users	Romosozumab	treatment	4	completed
NCT02418273	Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders	Denosumab	treatment	1 / 2	withdrawn
NCT03164928	Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis	Denosumab	treatment	3	completed